Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution

Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution

Silvia Antolín,1 Benigno Acea,2 Luis Albaina,2 Ángel Concha,3 Paz Santiago,3 Tomás García-Caballero,4 Joaquín J Mosquera,5 José Ramón Varela,5 Rafaela Soler,5 Lourdes Calvo1 1Medical Oncology Department, Breast Unit, A Coru...

Full description

Bibliographic Details
Main Authors: Antolín S, Acea B, Albaina L, Concha Á, Santiago P, García-Caballero T, Mosquera JJ, Varela JR, Soler R, Calvo L
Format: Article
Language:English
Published: Dove Medical Press 2018-12-01
Series:Breast Cancer : Targets and Therapy
Subjects:
Neoadjuvant therapy
HER2-positive breast cancer
pathologic complete response
cardiotoxicity
survival
Online Access:https://www.dovepress.com/primary-systemic-therapy-in-her2-positive-operable-breast-cancer-using-peer-reviewed-article-BCTT

Internet

https://www.dovepress.com/primary-systemic-therapy-in-her2-positive-operable-breast-cancer-using-peer-reviewed-article-BCTT

Similar Items